Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Study Overview: Eli Lilly and Company is spearheading a clinical study titled ‘A Phase 2, Multicenter, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for Reduction in Risk of Relapse to Cigarette Smoking in Adults (RENEW-Smk-1)’. The study aims to evaluate the effectiveness and safety of brenipatide in preventing relapse in adults who have recently quit smoking, highlighting its potential significance in smoking cessation efforts.
Intervention/Treatment: The study tests brenipatide, an experimental drug administered subcutaneously, against a placebo. Brenipatide is designed to help individuals maintain abstinence from smoking by reducing the risk of relapse.
Study Design: This is an interventional study with a randomized, parallel assignment. It employs a double-blind method, meaning both participants and care providers are unaware of who receives the actual drug or placebo. The primary goal is treatment-focused.
Study Timeline: The study is set to begin on October 31, 2025, with primary completion and estimated completion dates yet to be announced. The last update was also submitted on October 31, 2025, indicating the study is in its early stages and not yet recruiting participants.
Market Implications: This study could potentially bolster Eli Lilly’s stock performance by expanding its portfolio in the smoking cessation market, a sector with significant demand. Success in this trial could position Eli Lilly as a leader in this niche, possibly affecting competitor dynamics in the pharmaceutical industry.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.